sciensus pharma services limited
sciensus pharma services limited Company Information
Company Number
02759609
Next Accounts
Dec 2025
Industry
Other professional, scientific and technical activities (not including environmental consultancy or quantity surveying) n.e.c.
Other human health activities
Shareholders
halcyon acquisitions ltd
Group Structure
View All
Contact
Registered Address
107 station street, burton-on-trent, staffordshire, DE14 1SZ
Website
www.healthcare-at-home.co.uksciensus pharma services limited Estimated Valuation
Pomanda estimates the enterprise value of SCIENSUS PHARMA SERVICES LIMITED at £1.5b based on a Turnover of £1.7b and 0.93x industry multiple (adjusted for size and gross margin).
sciensus pharma services limited Estimated Valuation
Pomanda estimates the enterprise value of SCIENSUS PHARMA SERVICES LIMITED at £133.8m based on an EBITDA of £21.9m and a 6.1x industry multiple (adjusted for size and gross margin).
sciensus pharma services limited Estimated Valuation
Pomanda estimates the enterprise value of SCIENSUS PHARMA SERVICES LIMITED at £120.8m based on Net Assets of £53.7m and 2.25x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Sciensus Pharma Services Limited Overview
Sciensus Pharma Services Limited is a live company located in staffordshire, DE14 1SZ with a Companies House number of 02759609. It operates in the manufacture of pharmaceutical preparations sector, SIC Code 21200. Founded in October 1992, it's largest shareholder is halcyon acquisitions ltd with a 100% stake. Sciensus Pharma Services Limited is a mature, mega sized company, Pomanda has estimated its turnover at £1.7b with declining growth in recent years.
Upgrade for unlimited company reports & a free credit check
Sciensus Pharma Services Limited Health Check
Pomanda's financial health check has awarded Sciensus Pharma Services Limited a 4 rating. We use a traffic light system to show it exceeds the industry average on 6 measures and has 5 areas for improvement. Company Health Check FAQs
6 Strong
1 Regular
5 Weak
Size
annual sales of £1.7b, make it larger than the average company (£13.4m)
£1.7b - Sciensus Pharma Services Limited
£13.4m - Industry AVG
Growth
3 year (CAGR) sales growth of -4%, show it is growing at a slower rate (7%)
-4% - Sciensus Pharma Services Limited
7% - Industry AVG
Production
with a gross margin of 7.8%, this company has a higher cost of product (36.6%)
7.8% - Sciensus Pharma Services Limited
36.6% - Industry AVG
Profitability
an operating margin of 0.7% make it less profitable than the average company (5.2%)
0.7% - Sciensus Pharma Services Limited
5.2% - Industry AVG
Employees
with 1673 employees, this is above the industry average (49)
1673 - Sciensus Pharma Services Limited
49 - Industry AVG
Pay Structure
on an average salary of £43.2k, the company has an equivalent pay structure (£41.5k)
£43.2k - Sciensus Pharma Services Limited
£41.5k - Industry AVG
Efficiency
resulting in sales per employee of £992k, this is more efficient (£172k)
£992k - Sciensus Pharma Services Limited
£172k - Industry AVG
Debtor Days
it gets paid by customers after 28 days, this is earlier than average (38 days)
28 days - Sciensus Pharma Services Limited
38 days - Industry AVG
Creditor Days
its suppliers are paid after 72 days, this is slower than average (37 days)
72 days - Sciensus Pharma Services Limited
37 days - Industry AVG
Stock Days
it holds stock equivalent to 15 days, this is less than average (47 days)
15 days - Sciensus Pharma Services Limited
47 days - Industry AVG
Cash Balance
has cash to cover current liabilities for 0 weeks, this is less cash available to meet short term requirements (44 weeks)
0 weeks - Sciensus Pharma Services Limited
44 weeks - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 87.8%, this is a higher level of debt than the average (44.4%)
87.8% - Sciensus Pharma Services Limited
44.4% - Industry AVG
SCIENSUS PHARMA SERVICES LIMITED financials
Sciensus Pharma Services Limited's latest turnover from March 2024 is £1.7 billion and the company has net assets of £53.7 million. According to their latest financial statements, Sciensus Pharma Services Limited has 1,673 employees and maintains cash reserves of £1 million as reported in the balance sheet.
Data source: Companies House, Pomanda Estimates
| Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Oct 2019 | Oct 2018 | Oct 2017 | Oct 2016 | Oct 2015 | Oct 2014 | Oct 2013 | Oct 2012 | Oct 2011 | Oct 2010 | Oct 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | 1,659,600,000 | 1,647,474,000 | 1,508,701,000 | 1,901,232,000 | 1,350,354,000 | 1,819,673,000 | 1,728,171,000 | 1,567,658,000 | 1,374,786,000 | 1,327,955,000 | 1,177,134,000 | 1,108,660,000 | 979,969,000 | 813,951,000 | 675,568,000 |
| Other Income Or Grants | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost Of Sales | 1,529,550,000 | 1,524,506,000 | 1,392,979,000 | 1,754,275,000 | 1,249,297,000 | 1,724,770,000 | 1,632,748,000 | 1,487,627,000 | 1,299,376,000 | 1,262,881,000 | 1,105,840,000 | 1,039,213,000 | 918,551,000 | 754,306,000 | 622,583,000 |
| Gross Profit | 130,050,000 | 122,968,000 | 115,722,000 | 146,957,000 | 101,057,000 | 94,903,000 | 95,423,000 | 80,031,000 | 75,410,000 | 65,074,000 | 71,294,000 | 69,447,000 | 61,418,000 | 59,645,000 | 52,985,000 |
| Admin Expenses | 118,670,000 | 112,842,000 | 103,517,000 | 135,267,000 | 90,219,000 | 85,570,000 | 88,879,000 | 79,399,000 | 82,436,000 | 74,138,000 | 56,740,000 | 54,212,000 | 46,363,000 | 39,897,000 | 35,166,000 |
| Operating Profit | 11,380,000 | 10,126,000 | 12,205,000 | 11,690,000 | 10,838,000 | 9,333,000 | 6,544,000 | 632,000 | -7,026,000 | -9,064,000 | 14,554,000 | 15,235,000 | 15,055,000 | 19,748,000 | 17,819,000 |
| Interest Payable | 2,268,000 | 2,039,000 | 1,463,000 | 2,148,000 | 1,926,000 | 2,526,000 | 2,936,000 | 2,924,000 | 2,932,000 | 3,078,000 | 2,901,000 | 2,642,000 | 5,000 | 218,000 | 82,000 |
| Interest Receivable | 7,535,000 | 4,077,000 | 4,814,000 | 8,749,000 | 7,230,000 | 6,088,000 | 4,657,000 | 4,351,000 | 3,781,000 | 3,479,000 | 3,591,000 | 2,882,000 | 69,000 | 83,000 | 230,000 |
| Pre-Tax Profit | 16,647,000 | 14,366,000 | 15,556,000 | 24,135,000 | 16,918,000 | 12,895,000 | 8,265,000 | 2,059,000 | -6,177,000 | -8,663,000 | 15,244,000 | 15,475,000 | 15,119,000 | 19,613,000 | 17,967,000 |
| Tax | -3,995,000 | -3,963,000 | -3,182,000 | -3,984,000 | -3,435,000 | -2,828,000 | -267,000 | -793,000 | 1,429,000 | 3,195,000 | -1,237,000 | -994,000 | 189,000 | 361,000 | -1,041,000 |
| Profit After Tax | 12,652,000 | 10,403,000 | 12,374,000 | 20,151,000 | 13,483,000 | 10,067,000 | 7,998,000 | 1,266,000 | -4,748,000 | -5,468,000 | 14,007,000 | 14,481,000 | 15,308,000 | 19,974,000 | 16,926,000 |
| Dividends Paid | 60,000,000 | 0 | 91,587,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Retained Profit | -47,348,000 | 10,403,000 | -79,213,000 | 20,151,000 | 13,483,000 | 10,067,000 | 7,998,000 | 1,266,000 | -4,748,000 | -5,468,000 | 14,007,000 | 14,481,000 | 15,308,000 | 19,974,000 | 16,926,000 |
| Employee Costs | 72,342,000 | 70,215,000 | 64,313,000 | 82,294,000 | 52,301,000 | 48,320,000 | 49,901,000 | 49,388,000 | 52,723,000 | 43,165,000 | 36,268,000 | 33,334,000 | 30,355,000 | 26,478,000 | 21,947,000 |
| Number Of Employees | 1,673 | 1,687 | 1,671 | 1,545 | 1,403 | 1,333 | 1,320 | 1,774 | 1,717 | 1,421 | 1,359 | 1,295 | 1,251 | 1,072 | 918 |
| EBITDA* | 21,934,000 | 19,570,000 | 20,757,000 | 21,994,000 | 16,845,000 | 16,398,000 | 11,924,000 | 4,513,000 | -4,031,000 | -6,785,000 | 16,723,000 | 17,345,000 | 17,101,000 | 21,717,000 | 19,462,000 |
* Earnings Before Interest, Tax, Depreciation and Amortisation
| Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Oct 2019 | Oct 2018 | Oct 2017 | Oct 2016 | Oct 2015 | Oct 2014 | Oct 2013 | Oct 2012 | Oct 2011 | Oct 2010 | Oct 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tangible Assets | 11,420,000 | 7,735,000 | 8,575,000 | 10,013,000 | 10,080,000 | 8,603,000 | 11,233,000 | 6,956,000 | 5,756,000 | 5,594,000 | 4,975,000 | 6,009,000 | 5,917,000 | 6,480,000 | 6,116,000 |
| Intangible Assets | 23,193,000 | 22,925,000 | 22,341,000 | 18,953,000 | 13,839,000 | 11,495,000 | 13,902,000 | 11,582,000 | 7,995,000 | 6,011,000 | 290,000 | 420,000 | 553,000 | 680,000 | 21,000 |
| Investments & Other | 10,508,000 | 9,373,000 | 9,373,000 | 9,373,000 | 2,258,000 | 1,596,000 | 1,996,000 | 1,996,000 | 1,996,000 | 1,996,000 | 1,490,000 | 1,250,000 | 1,130,000 | 669,000 | 1,124,000 |
| Debtors (Due After 1 year) | 0 | 0 | 0 | 0 | 183,982,000 | 192,665,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Fixed Assets | 45,121,000 | 40,033,000 | 40,289,000 | 38,339,000 | 210,159,000 | 214,359,000 | 27,131,000 | 20,534,000 | 15,747,000 | 13,601,000 | 6,755,000 | 7,679,000 | 7,600,000 | 7,829,000 | 7,261,000 |
| Stock & work in progress | 66,067,000 | 59,060,000 | 56,316,000 | 60,871,000 | 52,248,000 | 56,067,000 | 83,142,000 | 67,035,000 | 63,248,000 | 49,568,000 | 37,278,000 | 33,888,000 | 33,943,000 | 24,979,000 | 22,352,000 |
| Trade Debtors | 127,563,000 | 136,935,000 | 141,289,000 | 139,229,000 | 131,015,000 | 204,873,000 | 204,928,000 | 184,785,000 | 154,560,000 | 158,644,000 | 145,651,000 | 130,899,000 | 113,551,000 | 97,663,000 | 75,349,000 |
| Group Debtors | 161,817,000 | 165,318,000 | 162,440,000 | 187,466,000 | 0 | 0 | 187,604,000 | 183,588,000 | 176,942,000 | 174,933,000 | 167,643,000 | 157,635,000 | 56,852,000 | 39,440,000 | 21,598,000 |
| Misc Debtors | 37,783,000 | 42,339,000 | 42,596,000 | 50,491,000 | 50,283,000 | 43,228,000 | 43,337,000 | 40,378,000 | 34,906,000 | 35,612,000 | 28,879,000 | 23,552,000 | 22,592,000 | 16,818,000 | 11,692,000 |
| Cash | 1,047,000 | 1,295,000 | 8,473,000 | 5,987,000 | 8,936,000 | 4,835,000 | 7,377,000 | 12,058,000 | 22,046,000 | 18,604,000 | 4,720,000 | 6,621,000 | 33,856,000 | 27,905,000 | 19,505,000 |
| misc current assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| total current assets | 394,277,000 | 404,947,000 | 411,114,000 | 444,044,000 | 242,482,000 | 309,003,000 | 526,388,000 | 487,844,000 | 451,702,000 | 437,361,000 | 384,171,000 | 352,595,000 | 260,794,000 | 206,805,000 | 150,496,000 |
| total assets | 439,398,000 | 444,980,000 | 451,403,000 | 482,383,000 | 452,641,000 | 523,362,000 | 553,519,000 | 508,378,000 | 467,449,000 | 450,962,000 | 390,926,000 | 360,274,000 | 268,394,000 | 214,634,000 | 157,757,000 |
| Bank overdraft | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Bank loan | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Trade Creditors | 302,870,000 | 303,228,000 | 301,239,000 | 281,506,000 | 268,865,000 | 324,136,000 | 356,003,000 | 315,171,000 | 269,586,000 | 248,669,000 | 195,482,000 | 172,984,000 | 158,569,000 | 121,478,000 | 83,989,000 |
| Group/Directors Accounts | 8,996,000 | 13,810,000 | 0 | 323,000 | 0 | 10,343,000 | 10,390,000 | 14,820,000 | 12,625,000 | 11,511,000 | 8,916,000 | 9,511,000 | 8,379,000 | 6,886,000 | 7,552,000 |
| other short term finances | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| hp & lease commitments | 1,597,000 | 1,507,000 | 0 | 1,362,000 | 899,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 29,000 | 30,000 |
| other current liabilities | 10,612,000 | 11,795,000 | 0 | 8,582,000 | 8,647,000 | 8,039,000 | 5,962,000 | 9,573,000 | 12,080,000 | 16,737,000 | 11,343,000 | 4,279,000 | 3,841,000 | 3,929,000 | 4,169,000 |
| total current liabilities | 324,075,000 | 330,340,000 | 301,239,000 | 291,773,000 | 278,411,000 | 342,518,000 | 372,355,000 | 339,564,000 | 294,291,000 | 276,917,000 | 215,741,000 | 186,774,000 | 170,789,000 | 132,322,000 | 95,740,000 |
| loans | 55,746,000 | 9,541,000 | 57,560,000 | 17,550,000 | 22,225,000 | 45,813,000 | 54,536,000 | 50,273,000 | 56,288,000 | 54,666,000 | 49,094,000 | 62,514,000 | 1,100,000 | 1,100,000 | 1,100,000 |
| hp & lease commitments | 3,388,000 | 306,000 | 0 | 1,732,000 | 2,365,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 30,000 |
| Accruals and Deferred Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 1,100,000 | 1,100,000 | 1,100,000 | 0 | 0 | 0 | 0 | 0 | 0 |
| provisions | 2,496,000 | 3,827,000 | 2,075,000 | 1,788,000 | 572,000 | 546,000 | 1,110,000 | 1,021,000 | 616,000 | 190,000 | 1,434,000 | 336,000 | 336,000 | 351,000 | 0 |
| total long term liabilities | 61,630,000 | 13,674,000 | 59,635,000 | 21,070,000 | 25,162,000 | 46,359,000 | 56,746,000 | 52,394,000 | 58,004,000 | 54,856,000 | 50,528,000 | 62,850,000 | 1,436,000 | 1,451,000 | 1,130,000 |
| total liabilities | 385,705,000 | 344,014,000 | 360,874,000 | 312,843,000 | 303,573,000 | 388,877,000 | 429,101,000 | 391,958,000 | 352,295,000 | 331,773,000 | 266,269,000 | 249,624,000 | 172,225,000 | 133,773,000 | 96,870,000 |
| net assets | 53,693,000 | 100,966,000 | 90,529,000 | 169,540,000 | 149,068,000 | 134,485,000 | 124,418,000 | 116,420,000 | 115,154,000 | 119,189,000 | 124,657,000 | 110,650,000 | 96,169,000 | 80,861,000 | 60,887,000 |
| total shareholders funds | 53,693,000 | 100,966,000 | 90,529,000 | 169,540,000 | 149,068,000 | 134,485,000 | 124,418,000 | 116,420,000 | 115,154,000 | 119,189,000 | 124,657,000 | 110,650,000 | 96,169,000 | 80,861,000 | 60,887,000 |
| Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Oct 2019 | Oct 2018 | Oct 2017 | Oct 2016 | Oct 2015 | Oct 2014 | Oct 2013 | Oct 2012 | Oct 2011 | Oct 2010 | Oct 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||||||||||
| Operating Profit | 11,380,000 | 10,126,000 | 12,205,000 | 11,690,000 | 10,838,000 | 9,333,000 | 6,544,000 | 632,000 | -7,026,000 | -9,064,000 | 14,554,000 | 15,235,000 | 15,055,000 | 19,748,000 | 17,819,000 |
| Depreciation | 3,049,000 | 3,128,000 | 3,597,000 | 4,664,000 | 2,600,000 | 2,438,000 | 2,476,000 | 1,989,000 | 2,340,000 | 1,773,000 | 2,039,000 | 1,977,000 | 1,919,000 | 1,917,000 | 1,626,000 |
| Amortisation | 7,505,000 | 6,316,000 | 4,955,000 | 5,640,000 | 3,407,000 | 4,627,000 | 2,904,000 | 1,892,000 | 655,000 | 506,000 | 130,000 | 133,000 | 127,000 | 52,000 | 17,000 |
| Tax | -3,995,000 | -3,963,000 | -3,182,000 | -3,984,000 | -3,435,000 | -2,828,000 | -267,000 | -793,000 | 1,429,000 | 3,195,000 | -1,237,000 | -994,000 | 189,000 | 361,000 | -1,041,000 |
| Stock | 7,007,000 | 2,744,000 | -4,555,000 | 60,871,000 | -3,819,000 | -27,075,000 | 16,107,000 | 3,787,000 | 13,680,000 | 12,290,000 | 3,390,000 | -55,000 | 8,964,000 | 2,627,000 | 22,352,000 |
| Debtors | -17,429,000 | -1,733,000 | -30,861,000 | 377,186,000 | -75,486,000 | 4,897,000 | 27,118,000 | 42,343,000 | -2,781,000 | 27,016,000 | 30,087,000 | 119,091,000 | 39,074,000 | 45,282,000 | 108,639,000 |
| Creditors | -358,000 | 1,989,000 | 19,733,000 | 281,506,000 | -55,271,000 | -31,867,000 | 40,832,000 | 45,585,000 | 20,917,000 | 53,187,000 | 22,498,000 | 14,415,000 | 37,091,000 | 37,489,000 | 83,989,000 |
| Accruals and Deferred Income | -1,183,000 | 11,795,000 | -8,582,000 | 8,582,000 | 608,000 | 2,077,000 | -3,611,000 | -2,507,000 | -4,657,000 | 5,394,000 | 7,064,000 | 438,000 | -88,000 | -240,000 | 4,169,000 |
| Deferred Taxes & Provisions | -1,331,000 | 1,752,000 | 287,000 | 1,788,000 | 26,000 | -564,000 | 89,000 | 405,000 | 426,000 | -1,244,000 | 1,098,000 | 0 | -15,000 | 351,000 | 0 |
| Cash flow from operations | 25,489,000 | 30,132,000 | 64,429,000 | -128,171,000 | 38,078,000 | 5,394,000 | 5,742,000 | 1,073,000 | 3,185,000 | 14,441,000 | 12,669,000 | -87,832,000 | 6,240,000 | 11,769,000 | -24,412,000 |
| Investing Activities | |||||||||||||||
| capital expenditure | |||||||||||||||
| Change in Investments | 1,135,000 | 0 | 0 | 9,373,000 | 662,000 | -400,000 | 0 | 0 | 0 | 506,000 | 240,000 | 120,000 | 461,000 | -455,000 | 1,124,000 |
| cash flow from investments | |||||||||||||||
| Financing Activities | |||||||||||||||
| Bank loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Group/Directors Accounts | -4,814,000 | 13,810,000 | -323,000 | 323,000 | -10,343,000 | -47,000 | -4,430,000 | 2,195,000 | 1,114,000 | 2,595,000 | -595,000 | 1,132,000 | 1,493,000 | -666,000 | 7,552,000 |
| Other Short Term Loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long term loans | 46,205,000 | -48,019,000 | 40,010,000 | 17,550,000 | -23,588,000 | -8,723,000 | 4,263,000 | -6,015,000 | 1,622,000 | 5,572,000 | -13,420,000 | 61,414,000 | 0 | 0 | 1,100,000 |
| Hire Purchase and Lease Commitments | 3,172,000 | 1,813,000 | -3,094,000 | 3,094,000 | 3,264,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -29,000 | -31,000 | 60,000 |
| other long term liabilities | 0 | 0 | 0 | 0 | 0 | -1,100,000 | 0 | 0 | 1,100,000 | 0 | 0 | 0 | 0 | 0 | 0 |
| share issue | |||||||||||||||
| interest | 5,267,000 | 2,038,000 | 3,351,000 | 6,601,000 | 5,304,000 | 3,562,000 | 1,721,000 | 1,427,000 | 849,000 | 401,000 | 690,000 | 240,000 | 64,000 | -135,000 | 148,000 |
| cash flow from financing | 49,905,000 | -30,324,000 | 40,146,000 | 176,957,000 | -24,263,000 | -6,308,000 | 1,554,000 | -2,393,000 | 5,398,000 | 8,568,000 | -13,325,000 | 62,786,000 | 1,528,000 | -832,000 | 52,821,000 |
| cash and cash equivalents | |||||||||||||||
| cash | -248,000 | -7,178,000 | 2,486,000 | 5,987,000 | 4,101,000 | -2,542,000 | -4,681,000 | -9,988,000 | 3,442,000 | 13,884,000 | -1,901,000 | -27,235,000 | 5,951,000 | 8,400,000 | 19,505,000 |
| overdraft | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| change in cash | -248,000 | -7,178,000 | 2,486,000 | 5,987,000 | 4,101,000 | -2,542,000 | -4,681,000 | -9,988,000 | 3,442,000 | 13,884,000 | -1,901,000 | -27,235,000 | 5,951,000 | 8,400,000 | 19,505,000 |
sciensus pharma services limited Credit Report and Business Information
Sciensus Pharma Services Limited Competitor Analysis
Perform a competitor analysis for sciensus pharma services limited by selecting its closest rivals, whether from the MANUFACTURING sector, other mega companies, companies in DE14 area or any other competitors across 12 key performance metrics.
sciensus pharma services limited Ownership
SCIENSUS PHARMA SERVICES LIMITED group structure
Sciensus Pharma Services Limited has 6 subsidiary companies.
Ultimate parent company
2 parents
SCIENSUS PHARMA SERVICES LIMITED
02759609
6 subsidiaries
sciensus pharma services limited directors
Sciensus Pharma Services Limited currently has 4 directors. The longest serving directors include Mr John Bradshaw (Dec 2013) and Sir Jonathan Asbridge (Jul 2016).
| officer | country | age | start | end | role |
|---|---|---|---|---|---|
| Mr John Bradshaw | 69 years | Dec 2013 | - | Director | |
| Sir Jonathan Asbridge | England | 65 years | Jul 2016 | - | Director |
| Ms Francesca Geretto | England | 47 years | Oct 2024 | - | Director |
| Mr Christian Tucat | England | 55 years | Nov 2024 | - | Director |
P&L
March 2024turnover
1.7b
+1%
operating profit
11.4m
+12%
gross margin
7.9%
+4.99%
turnover
Turnover, or revenue, is the amount of sales generated by a company within the financial year.
Balance Sheet
March 2024net assets
53.7m
-0.47%
total assets
439.4m
-0.01%
cash
1m
-0.19%
net assets
Total assets minus all liabilities
sciensus pharma services limited company details
company number
02759609
Type
Private limited with Share Capital
industry
74909 - Other professional, scientific and technical activities (not including environmental consultancy or quantity surveying) n.e.c.
86900 - Other human health activities
21200 - Manufacture of pharmaceutical preparations
incorporation date
October 1992
age
33
incorporated
UK
ultimate parent company
accounts
Full Accounts
last accounts submitted
March 2024
previous names
healthcare at home ltd (April 2022)
health care at home limited (December 1992)
accountant
-
auditor
KPMG LLP
address
107 station street, burton-on-trent, staffordshire, DE14 1SZ
Bank
-
Legal Advisor
-
sciensus pharma services limited Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We found 17 charges/mortgages relating to sciensus pharma services limited. Currently there are 3 open charges and 14 have been satisfied in the past.
sciensus pharma services limited Capital Raised & Share Issues BETA
When a company issues new shares, e.g. to new investors following a funding round, it is required to notify Companies House within one month of making an allotment of shares.
Click to start generating capital raising & share issue transactions for SCIENSUS PHARMA SERVICES LIMITED. This can take several minutes, an email will notify you when this has completed.
sciensus pharma services limited Companies House Filings - See Documents
| date | description | view/download |
|---|
